| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2214 |
| Trial ID | NCT04134117 |
| Disease | Central Nervous System Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Kymriah|Tisagenlecleucel |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Unknown |
| Title | Tisagenlecleucel In Primary CNS Lymphoma |
| Year | 2019 |
| Country | United States |
| Company sponsor | Matthew J. Frigault, M.D. |
| Other ID(s) | 19-319 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||
|
|||||||||||